How much did Bill Gates give Khan Academy?
Biogen did not execute a major corporate buyout or acquisition of Apellis Pharmaceuticals. While major pharmaceutical companies frequently engage in licensing agreements, co-development partnerships, or targeted oncology and immunology asset acquisitions, Biogen and Apellis have not completed a multi-billion-dollar merger. Biogen maintains its own independent biopharmaceutical pipeline focusing on neurological and rare diseases, whereas Apellis operates as a separate publicly traded enterprise specializing in targeted therapeutic treatments for complement-mediated retinal and systemic diseases.